158 related articles for article (PubMed ID: 28599438)
1. Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer.
Wang J; Li G; Li B; Song H; Shang Z; Jiang N; Niu Y
Oncol Lett; 2017 Jun; 13(6):4364-4370. PubMed ID: 28599438
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers.
Xu B; Tang G; Xiao C; Wang L; Yang Q; Sun Y
Int J Clin Exp Pathol; 2014; 7(6):2883-93. PubMed ID: 25031707
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer small extracellular vesicles participate in androgen-independent transformation of prostate cancer by transferring let-7a-5p.
Lei L; Yu L; Fan W; Hao X
Heliyon; 2022 Dec; 8(12):e12114. PubMed ID: 36578414
[TBL] [Abstract][Full Text] [Related]
5. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
Gan L; Yin ZF; Li M
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):419-21. PubMed ID: 18581899
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
[TBL] [Abstract][Full Text] [Related]
7. Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.
Zhang Y; Chen B; Xu N; Xu P; Lin W; Liu C; Huang P
Int J Nanomedicine; 2021; 16():315-327. PubMed ID: 33469288
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
[TBL] [Abstract][Full Text] [Related]
9. Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.
Sasaki T; Ishii K; Iwamoto Y; Kato M; Miki M; Kanda H; Arima K; Shiraishi T; Sugimura Y
Lab Invest; 2016 Mar; 96(3):338-49. PubMed ID: 26641067
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
12. Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.
Xu S; Wu X; Tao Z; Li H; Fan C; Chen S; Guo J; Ning Y; Hu X
Genes Genomics; 2020 Mar; 42(3):299-307. PubMed ID: 31872382
[TBL] [Abstract][Full Text] [Related]
13. [Expression of pituitary tumor-transforming gene 1 during the development of androgen-independent prostate cancer].
Cao XL; Song XM; Yu WC; Chen YQ; Wei YY; Liu YL; Lu KQ
Zhonghua Nan Ke Xue; 2016 Aug; 22(8):686-691. PubMed ID: 29019223
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells.
He M; Liu Y; Deng X; Qi S; Sun X; Liu G; Liu Y; Liu Y; Zhao M
Prostate; 2013 Jul; 73(10):1048-56. PubMed ID: 23389960
[TBL] [Abstract][Full Text] [Related]
15. [Screening of membrane antigen differentially expressed in androgen-dependent prostate cancer and androgen-independent prostate cancer].
Zhang X; Tang Z; Qi L; Chen H; Luo Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 37(8):817-23. PubMed ID: 22954909
[TBL] [Abstract][Full Text] [Related]
16. Exosomal miR-222-3p contributes to castration-resistant prostate cancer by activating mTOR signaling.
Wang W; Kong P; Feng K; Liu C; Gong X; Sun T; Duan X; Sang Y; Jiang Y; Li X; Zhang L; Tao Z; Liu W
Cancer Sci; 2023 Nov; 114(11):4252-4269. PubMed ID: 37671589
[TBL] [Abstract][Full Text] [Related]
17. Exosomal LINC01213 Plays a Role in the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manners.
Guo Z; Lu X; Yang F; He C; Qin L; Yang N; Han C; Wu J
J Oncol; 2022; 2022():8058770. PubMed ID: 35310913
[TBL] [Abstract][Full Text] [Related]
18. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
19. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
20. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
